Rosiglitazone is a thiazolidinedione antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
For this indication, competent medicine agencies globally authorize below treatments:
4 - 8 mg
From 2 To 4 mg 2 time(s) per day every day
Rosiglitazone may be administered at a starting dose of 4 mg either as a single daily dose or in 2 divided doses. For patients who respond inadequately following 8 to 12 weeks of treatment, as determined by reduction in fasting plasma glucose (FPG), the dose may be increased to 8 mg daily. Increases in the dose of rosiglitazone should be accompanied by careful monitoring for adverse events related to fluid retention.
The total daily dose of rosiglitazone should not exceed 8 mg.
Patients receiving rosiglitazone in combination with other hypoglycemic agents may be at risk for hypoglycemia, and a reduction in the dose of the concomitant agent may be necessary.
Rosiglitazone may be taken with or without food.